Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Remicade to Remsima serum concentration study in stable remission
2014-004904-31Phase 4Active
- Sponsor
- Mundipharma
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis and rheumatoid arthritis (RA), sponsored by Mundipharma. Primary endpoint: Infliximab serum concentration at 16 weeks after switch. Started Jan 2015; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-004904-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004904-31.